These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20542839)

  • 21. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
    Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G
    Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravascular large B-cell lymphoma: successful therapy with bendamustine and rituximab.
    Mleczko A; Franke I; Scheinpflug K; Gollnick H; Leverkus M
    Acta Derm Venereol; 2009; 89(4):425-7. PubMed ID: 19688165
    [No Abstract]   [Full Text] [Related]  

  • 23. Intralesional agents in the management of cutaneous malignancy: a review.
    Good LM; Miller MD; High WA
    J Am Acad Dermatol; 2011 Feb; 64(2):413-22. PubMed ID: 20334952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma.
    Perez-Gala S; Delgado-Jimenez Y; Goiriz R; Fraga J; Garcia-Diez A; Fernandez-Herrera J
    Arch Dermatol; 2006 Nov; 142(11):1516-7. PubMed ID: 17116855
    [No Abstract]   [Full Text] [Related]  

  • 25. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cutaneous marginal zone B-cell lymphoma treated with rituximab].
    Pedraz J; Delgado Y; Aragüés M; Fraga J; García-Díez A; Fernández-Herrera J
    Actas Dermosifiliogr; 2005 Nov; 96(9):593-7. PubMed ID: 16476304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
    Meinhardt A; Burkhardt B; Zimmermann M; Borkhardt A; Kontny U; Klingebiel T; Berthold F; Janka-Schaub G; Klein C; Kabickova E; Klapper W; Attarbaschi A; Schrappe M; Reiter A;
    J Clin Oncol; 2010 Jul; 28(19):3115-21. PubMed ID: 20516455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
    Bennett M; Yegena S; Dave HP; Schechter GP
    Hematol Oncol; 2008 Jun; 26(2):114. PubMed ID: 18271062
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary cutaneous B-cell lymphoma mimicking pyoderma gangrenosum: first-line treatment with rituximab.
    Lami MC; Vabres P; Dreyfus B; Germain T; Guillet G
    Br J Dermatol; 2004 Jul; 151(1):250-2. PubMed ID: 15270913
    [No Abstract]   [Full Text] [Related]  

  • 31. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
    Fernández-Guarino M; Ortiz-Romero PL; Fernández-Misa R; Montalbán C
    Actas Dermosifiliogr; 2014 Jun; 105(5):438-45. PubMed ID: 23540593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing rituximab in B-cell lymphoma.
    Horning SJ
    J Clin Oncol; 2005 Feb; 23(6):1056-8. PubMed ID: 15657408
    [No Abstract]   [Full Text] [Related]  

  • 33. Intralesional Rituximab Treatment for Primary Cutaneous B-cell Lymphoma: Nine Finnish Cases.
    Väkevä L; Ranki A; Mälkönen T
    Acta Derm Venereol; 2016 Mar; 96(3):396-7. PubMed ID: 26525093
    [No Abstract]   [Full Text] [Related]  

  • 34. Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab.
    Nagasaka A; Matsue H; Kawamura T; Kanzaki M; Inozume T; Nakamura Y; Shimzu A; Shibagaki N; Yanagi M; Shimada S
    J Dermatol; 2006 May; 33(5):377-9. PubMed ID: 16700675
    [No Abstract]   [Full Text] [Related]  

  • 35. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence.
    Attias D; Weitzman S
    Curr Opin Pediatr; 2008 Feb; 20(1):17-22. PubMed ID: 18197034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
    Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
    Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Febrile cellulitis surrounding a scar revealing a large immunoblastic B-cell lymphoma].
    Charavin-Cocuzza M; Templier I; Simon A; Salameire D; Cuchet E; Reymond JL; Beani JC; Leccia MT
    Ann Dermatol Venereol; 2008 Dec; 135(12):848-51. PubMed ID: 19084696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma.
    Perry A; Vincent BJ; Parker SR
    Br J Dermatol; 2010 Jul; 163(1):223-5. PubMed ID: 20394622
    [No Abstract]   [Full Text] [Related]  

  • 39. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
    Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
    Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.